Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

CTXR vs ETON vs PRGO vs TLRY vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CTXR
Citius Pharmaceuticals, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$12M
5Y Perf.-97.1%
ETON
Eton Pharmaceuticals, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$839M
5Y Perf.+544.6%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-78.6%
TLRY
Tilray Brands, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$660M
5Y Perf.-43.6%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+364.2%

CTXR vs ETON vs PRGO vs TLRY vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CTXR logoCTXR
ETON logoETON
PRGO logoPRGO
TLRY logoTLRY
MCK logoMCK
IndustryBiotechnologyBiotechnologyDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericMedical - Distribution
Market Cap$12M$839M$1.61B$660M$92.15B
Revenue (TTM)$0.00$80M$4.18B$1.17B$403.43B
Net Income (TTM)$-37M$-5M$-1.82B$-2.95B$4.76B
Gross Margin53.5%34.2%28.0%3.6%
Operating Margin-1.1%-4.1%-266.0%1.5%
Forward P/E33.2x5.5x16.7x
Total Debt$2M$9M$3.97B$451M$7.39B
Cash & Equiv.$4M$26M$532M$304M$5.69B

CTXR vs ETON vs PRGO vs TLRY vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CTXR
ETON
PRGO
TLRY
MCK
StockMay 20May 26Return
Citius Pharmaceutic… (CTXR)1002.9-97.1%
Eton Pharmaceutical… (ETON)100644.6+544.6%
Perrigo Company plc (PRGO)10021.4-78.6%
Tilray Brands, Inc. (TLRY)10056.4-43.6%
McKesson Corporation (MCK)100464.2+364.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: CTXR vs ETON vs PRGO vs TLRY vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. ETON and TLRY also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
CTXR
Citius Pharmaceuticals, Inc.
The Healthcare Pick

Among these 5 stocks, CTXR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
ETON
Eton Pharmaceuticals, Inc.
The Growth Play

ETON ranks third and is worth considering specifically for growth exposure and long-term compounding.

  • Rev growth 104.9%, EPS growth -13.3%, 3Y rev CAGR 55.5%
  • 396.3% 10Y total return vs MCK's 348.1%
  • Lower volatility, beta 0.66, Low D/E 35.4%, current ratio 1.57x
  • 104.9% revenue growth vs CTXR's -100.0%
Best for: growth exposure and long-term compounding
PRGO
Perrigo Company plc
The Defensive Pick

PRGO is the #2 pick in this set and the best alternative if defensive is your priority.

  • Beta 1.18, yield 9.8%, current ratio 2.76x
  • Lower P/E (5.5x vs 16.7x)
  • 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
Best for: defensive
TLRY
Tilray Brands, Inc.
The Momentum Pick

TLRY is the clearest fit if your priority is momentum.

  • +12.1% vs PRGO's -51.2%
Best for: momentum
MCK
McKesson Corporation
The Income Pick

MCK carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 17 yrs, beta 0.04, yield 0.4%
  • 1.2% margin vs TLRY's -252.6%
  • Beta 0.04 vs CTXR's 2.76
  • 5.7% ROA vs TLRY's -100.6%, ROIC 5.4% vs -66.2%
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthETON logoETON104.9% revenue growth vs CTXR's -100.0%
ValuePRGO logoPRGOLower P/E (5.5x vs 16.7x)
Quality / MarginsMCK logoMCK1.2% margin vs TLRY's -252.6%
Stability / SafetyMCK logoMCKBeta 0.04 vs CTXR's 2.76
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
Momentum (1Y)TLRY logoTLRY+12.1% vs PRGO's -51.2%
Efficiency (ROA)MCK logoMCK5.7% ROA vs TLRY's -100.6%, ROIC 5.4% vs -66.2%

CTXR vs ETON vs PRGO vs TLRY vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CTXRCitius Pharmaceuticals, Inc.

Segment breakdown not available.

ETONEton Pharmaceuticals, Inc.
FY 2025
Product Sales and Royalties
95.9%$77M
License
4.1%$3M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
TLRYTilray Brands, Inc.
FY 2025
Cannabis Segment
36.1%$331M
Distribution Revenue
29.6%$271M
Beverage Alcohol Business
27.7%$253M
Wellness Business
6.6%$60M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

CTXR vs ETON vs PRGO vs TLRY vs MCK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLETONLAGGINGTLRY

Income & Cash Flow (Last 12 Months)

ETON leads this category, winning 3 of 6 comparable metrics.

MCK and CTXR operate at a comparable scale, with $403.4B and $0 in trailing revenue. Profitability is closely matched — net margins range from 1.2% (MCK) to -2.5% (TLRY). On growth, ETON holds the edge at +82.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCTXR logoCTXRCitius Pharmaceut…ETON logoETONEton Pharmaceutic…PRGO logoPRGOPerrigo Company p…TLRY logoTLRYTilray Brands, In…MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$0$80M$4.2B$1.2B$403.4B
EBITDAEarnings before interest/tax-$38M$2M$58M-$3.0B$6.8B
Net IncomeAfter-tax profit-$37M-$5M-$1.8B-$2.9B$4.8B
Free Cash FlowCash after capex-$27M-$333,000$108M-$94M$6.0B
Gross MarginGross profit ÷ Revenue+53.5%+34.2%+28.0%+3.6%
Operating MarginEBIT ÷ Revenue-1.1%-4.1%-2.7%+1.5%
Net MarginNet income ÷ Revenue-5.8%-43.5%-2.5%+1.2%
FCF MarginFCF ÷ Revenue-0.4%+2.6%-8.1%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%+82.7%-7.2%+3.0%+6.0%
EPS Growth (YoY)Latest quarter vs prior year+74.1%+3.4%-56.4%+70.7%+37.0%
ETON leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 3 of 6 comparable metrics.

On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than MCK's 18.7x.

MetricCTXR logoCTXRCitius Pharmaceut…ETON logoETONEton Pharmaceutic…PRGO logoPRGOPerrigo Company p…TLRY logoTLRYTilray Brands, In…MCK logoMCKMcKesson Corporat…
Market CapShares × price$12M$839M$1.6B$660M$92.1B
Enterprise ValueMkt cap + debt − cash$9M$822M$5.1B$806M$93.8B
Trailing P/EPrice ÷ TTM EPS-0.19x-182.47x-1.14x-0.17x29.25x
Forward P/EPrice ÷ next-FY EPS est.33.19x5.53x16.66x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple7.42x18.74x
Price / SalesMarket cap ÷ Revenue10.49x0.38x0.59x0.26x
Price / BookPrice ÷ Book value/share0.09x31.91x0.55x0.25x
Price / FCFMarket cap ÷ FCF82.33x11.12x17.63x
PRGO leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 6 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-137 for TLRY. CTXR carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs TLRY's 4/9, reflecting solid financial health.

MetricCTXR logoCTXRCitius Pharmaceut…ETON logoETONEton Pharmaceutic…PRGO logoPRGOPerrigo Company p…TLRY logoTLRYTilray Brands, In…MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity-48.3%-18.8%-50.7%-136.5%+3.0%
ROA (TTM)Return on assets-28.6%-4.8%-19.8%-100.6%+5.7%
ROICReturn on invested capital-39.5%-2.6%+3.7%-66.2%+5.4%
ROCEReturn on capital employed-46.2%-1.5%+4.3%-78.1%+30.5%
Piotroski ScoreFundamental quality 0–945446
Debt / EquityFinancial leverage0.02x0.35x1.35x0.22x
Net DebtTotal debt minus cash-$3M-$17M$3.4B$147M$1.7B
Cash & Equiv.Liquid assets$4M$26M$532M$304M$5.7B
Total DebtShort + long-term debt$2M$9M$4.0B$451M$7.4B
Interest CoverageEBIT ÷ Interest expense-143.54x-1.07x-7.20x-89.43x33.79x
MCK leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ETON leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in ETON five years ago would be worth $39,216 today (with dividends reinvested), compared to $121 for CTXR. Over the past 12 months, TLRY leads with a +1209.3% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors ETON at 107.5% vs CTXR's -72.7% — a key indicator of consistent wealth creation.

MetricCTXR logoCTXRCitius Pharmaceut…ETON logoETONEton Pharmaceutic…PRGO logoPRGOPerrigo Company p…TLRY logoTLRYTilray Brands, In…MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date-22.9%+90.8%-13.5%-41.8%-8.5%
1-Year ReturnPast 12 months-6.2%+80.0%-51.2%+1209.3%+4.6%
3-Year ReturnCumulative with dividends-98.0%+793.9%-58.1%+103.6%+106.4%
5-Year ReturnCumulative with dividends-98.8%+292.2%-60.1%-65.0%+286.9%
10-Year ReturnCumulative with dividends-99.9%+396.3%-77.7%-74.7%+348.1%
CAGR (3Y)Annualised 3-year return-72.7%+107.5%-25.2%+26.7%+27.3%
ETON leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ETON and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than CTXR's 2.76 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ETON currently trades 96.0% from its 52-week high vs CTXR's 26.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCTXR logoCTXRCitius Pharmaceut…ETON logoETONEton Pharmaceutic…PRGO logoPRGOPerrigo Company p…TLRY logoTLRYTilray Brands, In…MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5002.63x0.56x1.21x2.04x-0.02x
52-Week HighHighest price in past year$2.48$32.30$28.44$15.70$999.00
52-Week LowLowest price in past year$0.57$13.09$9.23$0.35$637.00
% of 52W HighCurrent price vs 52-week peak+26.4%+96.0%+41.2%+36.1%+75.3%
RSI (14)Momentum oscillator 0–10041.171.760.937.916.2
Avg Volume (50D)Average daily shares traded746K392K3.4M4.7M757K
Evenly matched — ETON and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.

Analyst consensus: ETON as "Buy", PRGO as "Hold", TLRY as "Hold", MCK as "Buy". Consensus price targets imply 208.9% upside for PRGO (target: $36) vs -19.4% for ETON (target: $25). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.

MetricCTXR logoCTXRCitius Pharmaceut…ETON logoETONEton Pharmaceutic…PRGO logoPRGOPerrigo Company p…TLRY logoTLRYTilray Brands, In…MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyHoldHoldBuy
Price TargetConsensus 12-month target$25.00$36.20$10.00$994.86
# AnalystsCovering analysts6362031
Dividend YieldAnnual dividend ÷ price+9.8%+0.4%
Dividend StreakConsecutive years of raises11017
Dividend / ShareAnnual DPS$1.15$2.69
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%+3.4%
Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.
Key Takeaway

ETON leads in 2 of 6 categories (Income & Cash Flow, Total Returns). PRGO leads in 1 (Valuation Metrics). 2 tied.

Best OverallEton Pharmaceuticals, Inc. (ETON)Leads 2 of 6 categories
Loading custom metrics...

CTXR vs ETON vs PRGO vs TLRY vs MCK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is CTXR or ETON or PRGO or TLRY or MCK a better buy right now?

For growth investors, Eton Pharmaceuticals, Inc.

(ETON) is the stronger pick with 104. 9% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). McKesson Corporation (MCK) offers the better valuation at 29. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Eton Pharmaceuticals, Inc. (ETON) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CTXR or ETON or PRGO or TLRY or MCK?

On forward P/E, Perrigo Company plc is actually cheaper at 5.

5x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — CTXR or ETON or PRGO or TLRY or MCK?

Over the past 5 years, Eton Pharmaceuticals, Inc.

(ETON) delivered a total return of +292. 2%, compared to -98. 8% for Citius Pharmaceuticals, Inc. (CTXR). Over 10 years, the gap is even starker: ETON returned +374. 4% versus CTXR's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CTXR or ETON or PRGO or TLRY or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Citius Pharmaceuticals, Inc. 's 2. 63β — meaning CTXR is approximately -16163% more volatile than MCK relative to the S&P 500. On balance sheet safety, Citius Pharmaceuticals, Inc. (CTXR) carries a lower debt/equity ratio of 2% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — CTXR or ETON or PRGO or TLRY or MCK?

By revenue growth (latest reported year), Eton Pharmaceuticals, Inc.

(ETON) is pulling ahead at 104. 9% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Citius Pharmaceuticals, Inc. grew EPS 43. 4% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ETON leads at 55. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CTXR or ETON or PRGO or TLRY or MCK?

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — ETON leads at 53. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CTXR or ETON or PRGO or TLRY or MCK more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 33. 2x for Eton Pharmaceuticals, Inc. — 27. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.

08

Which pays a better dividend — CTXR or ETON or PRGO or TLRY or MCK?

In this comparison, PRGO (9.

8% yield), MCK (0. 4% yield) pay a dividend. CTXR, ETON, TLRY do not pay a meaningful dividend and should not be held primarily for income.

09

Is CTXR or ETON or PRGO or TLRY or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02), +339. 0% 10Y return). Citius Pharmaceuticals, Inc. (CTXR) carries a higher beta of 2. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +339. 0%, CTXR: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CTXR and ETON and PRGO and TLRY and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTXR is a small-cap quality compounder stock; ETON is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; TLRY is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. PRGO pays a dividend while CTXR, ETON, TLRY, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

CTXR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ETON

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 41%
  • Gross Margin > 32%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

TLRY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CTXR and ETON and PRGO and TLRY and MCK on the metrics below

Revenue Growth>
%
(CTXR: -100.0% · ETON: 82.7%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.